Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 2009-2021

  Silvers, Amy L ^a   Lin, Lin ^a   Bass, Adam J ^b   Chen, Guoan ^a   Wang, Zhuwen ^a   Thomas, Dafydd G ^a   Lin, Jules ^a   Giordano, Thomas J ^a   Orringer, Mark B ^a   Beer, David G ^a   Chang, Andrew C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CISPLATIN; DNA METHYLTRANSFERASE; MESSENGER RNA; ONCOPROTEIN; SELENIUM BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE COURSE; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; SELENIUM-BINDING PROTEINS; TISSUE ARRAY ANALYSIS;

EID: 77950666530     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2801     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Rudolph RE, Vaughan TL, Kristal AR, et al. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst 2003;95:750-757
3. Fischer JL, Mihelc EM, Pollok KE, Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 2007;6:355-361
4. Hu H, Li G-X, Wang L, Watts J, Combs GF, Jr., Lu J. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 2008;14:1150-1158
5. Behne D, Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr 2001;21:453-473
6. Jeong J-Y, Wang Y, Sytkowski AJ. Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner. Biochem Biophys Res Commun 2009;379:583-588
7. Chang PW, Tsui SK, Liew C, Lee CC, Waye MM, Fung KP. Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J Cell Biochem 1997;64:217-224
8. Yang M, Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 1998;58:3150-3153
9. Chen G, Wang H, Miller CT, et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 2004;202:321-329
10. Huang KC, Park DC, Ng SK, et al. Selenium binding protein 1 in ovarian cancer. Int J Cancer 2006;118:2433-2440
11. Kim H, Kang HJ, You KT, et al. Suppression of human seleniumbinding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006;6:3466-3476
12. Li T, Yang W, Li M, et al. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 2008;52:1289-1299
13. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004;10:849-859
14. Luthra MG, Ajani JA, Izzo J, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 2007;13:912-919
15. Morrison DG, Oborn CJ, Medina D. Selenite distribution in log and confluent growth phase murine mammary epithelial cells. Cancer Lett 1988;43:227-236
16. Cho YM, Bae SH, Choi BK, et al. Differential expression of the liver proteome in senescence accelerated mice. Proteomics 2003;3:1883-1894
17. Hughes S, Nambu Y, Soldes O, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997;57:5571-5578
18. Stoner G, Kaighn M, Reddel R, et al. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res 1991;51:365-371
19. Lin J, Raoof DA, Wang Z, et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia 2006;8:1062-1071
20. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264
21. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408
23. Kononen J, Bubendorf L, Kallionimeni A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847
24. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898
25. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-1242
26. Maru DM, Luthra R, Correa AM, et al. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 2009;115:1576-1585
27. He C, Zuo Z, Chen H, et al. Genome-wide detection of testis- and testicular cancer-specific alternative splicing. Carcinogenesis 2007;28:2484-2490
28. Marenholz I, Zirra M, Fischer DF, Backendorf C, Ziegler A, Mischke D. Identification of human epidermal differentiation complex (EDC)-encoded genes by subtractive hybridization of entire YACs to a gridded keratinocyte cDNA library. Genome Res 2001;11:341-355
29. Elder JT, Zhao X. Evidence for local control of gene expression in the epidermal differentiation complex. Exp Dermatol 2002;11:406-412
30. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006;28:378-386
31. Mattow J, Demuth I, Haeselbarth G, Jungblut PR, Klose J. Seleniumbinding protein 2, the major hepatic target for acetaminophen, shows sex differences in protein abundance. Electrophoresis 2006;27:1683-1691
32. Blot WJ, Li J-Y, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1491
33. Lu J, Jiang C, Kaeck M, et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50:213-219
34. Park JM, Kim A, Oh JH, Chung AS. Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-κB activation. Carcinogenesis 2007;28:837-847
35. Yoon SO, Kim MM, Chung AS. Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem 2001;276:20085-20092
36. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-3070
37. Zhu Z, Jiang W, Ganther HE, Thompson HJ. Mechanisms of cell cycle arrest by methylseleninic acid. Cancer Res 2002;62:156-164
38. Ip C, Hayes C, Budnick RM, Ganther HE. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991;51:595-600.
39. Hu H, Jiang C, Ip C, Rustum YM, Lu J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005;11:2379-2388
40. Bansal M, Mukhopadhyay T, Scott J, Cook R, Mukhopadhyay R, Medina D. DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 1990;11:2071-2073
41. Morrison DG, Dishart MK, Medina D. Intracellular 58-kd selenoprotein levels correlate with inhibition of DNA synthesis in mammary epithelial cells. Carcinogenesis 1988;9:1801-1810
42. Davis CD, Uthus EO. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. J Nutr 2003;133:2907-2914
43. Lee JI, Nian H, Cooper AJ, et al. α-Keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res (Phila Pa) 2009;2:683-693
44. Xiang N, Zhao R, Song G, Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis 2008;29:2175-2181
45. Scortegagna M, Martin RJ, Kladney RD, Neumann RG, Arbeit JM. Hypoxia-inducible factor-1α suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. Cancer Res 2009;69:2638-2646
46. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732
47. Li GX, Hu H, Jiang C, Schuster T, Lu J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 2007;120:2034-2043